Favipiravir: Pharmacokinetics and Concerns About Clinical Trials for 2019-nCoV Infection.

https://www.ncbi.nlm.nih.gov/research/coronavirus/publication/32246834

Favipiravir provides a substitute for compassionate use in COVID-19 based on its mechanism of action inhibiting virus RdRp and safety data in previous clinical studies. Data obtained from influenza treatment and proof-of-concept clinical trial in Ebola Virus Disease aids the determination of dose regimen in clinical trials or experimental use of the drug in COVID-19. However, the exact efficacy of favipiravir awaits further clinical confirmation. Potential drug-drug interactions (DDIs) due to Aldehyde Oxidase (AO) inhibition should not be ignored in the clinical setting.

Tags: